How would you measure the success of Cerus's INTERCEPT Blood System for platelets?

Introduction

Measuring the success of Cerus's INTERCEPT Blood System for platelets requires a comprehensive approach that considers multiple stakeholders and metrics. This innovative medical technology aims to enhance blood safety by reducing pathogens in platelet components. To effectively evaluate its success, we'll examine key performance indicators across various dimensions, including clinical outcomes, operational efficiency, and market adoption.

Step 1

Product Context

The INTERCEPT Blood System for platelets is a pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in platelet components. Key stakeholders include:

1. Blood centers and hospitals: Seeking to improve blood safety and reduce transfusion-transmitted infections
2. Patients: Benefiting from reduced risk of transfusion-related complications
3. Regulatory bodies: Ensuring compliance with blood safety standards
4. Healthcare payers: Interested in cost-effectiveness and potential reduction in treatment costs

User flow:

1. Blood collection from donors
2. Platelet separation and processing
3. INTERCEPT treatment application
4. Quality control and testing
5. Storage and distribution to hospitals
6. Transfusion to patients

The INTERCEPT system aligns with Cerus's mission to improve blood safety globally. It competes with traditional screening methods and other pathogen reduction technologies, offering a more comprehensive approach to blood safety.

Product Lifecycle Stage: The INTERCEPT Blood System for platelets is in the growth stage, with increasing adoption in various markets but still potential for significant expansion.

Hardware considerations:

• Manufacturing scalability to meet growing demand
• Supply chain management for consistent availability of treatment sets
• Service infrastructure for system maintenance and support